MRK — Merck & Co., Inc.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 310158 ·
Last close
$143.37
Market Cap
$353.44B
52W High
$156.00
52W Low
$89.48
ADV30
9,473,245
Next earnings
2026-10-29
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | — | — | — | — | — | — | — |
| Jun 2026 | 16,607,000,000 | 12,212,000,000 | -433,000,000 | -1,335,000,000 | 129,802,000,000 | 6,849,000,000 | 87,818,000,000 |
| Mar 2026 | 16,286,000,000 | 12,091,000,000 | -3,201,000,000 | -4,240,000,000 | 128,685,000,000 | 5,327,000,000 | 82,754,000,000 |
| Dec 2025 | 16,400,000,000 | 10,849,000,000 | 4,065,000,000 | 2,963,000,000 | 136,866,000,000 | 14,565,000,000 | 84,204,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$18,703,000,000
Investing CF
$-28,332,000,000
Financing CF
$1,100,000,000
CapEx
$-3,957,000,000
Dividends Paid
$-8,366,000,000
Buybacks
$-3,536,000,000
EPS Diluted TTM
$0.97
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$66,223,000,000
Inventory
$6,164,000,000
Receivables
$12,744,000,000
ST Investments
$100,000,000
EBIT TTM
$6,723,000,000
Pretax Income TTM
$4,762,000,000
Interest Exp TTM
$1,961,000,000
Analysts
26
Yahoo Snapshot (yfinance, live)
Total Revenue
$67,377,999,872
EBITDA
$29,492,000,768
Free Cash Flow
$14,024,250,368
Enterprise Value
$406,031,499,264
Total Cash
$9,649,999,872
Total Debt
$53,902,999,552
Shares Out
2,465,245,688
Trailing EPS
$0.99
Book Value
$18.20
ROE
5.1%
ROA
11.3%
Div Yield
2.32%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 65,011,000,000 | 22,107,000,000 | 18,254,000,000 | 136,866,000,000 | 84,204,000,000 | 52,606,000,000 | 16,472,000,000 |
| Dec 2024 | 64,168,000,000 | 20,221,000,000 | 17,117,000,000 | 117,106,000,000 | 70,734,000,000 | 46,313,000,000 | 21,468,000,000 |
| Dec 2023 | 60,115,000,000 | 2,954,000,000 | 365,000,000 | 106,675,000,000 | 69,040,000,000 | 37,581,000,000 | 13,006,000,000 |
| Dec 2022 | 59,283,000,000 | 18,282,000,000 | 14,519,000,000 | 109,160,000,000 | 63,102,000,000 | 45,991,000,000 | 19,095,000,000 |
TTM Snapshot
Revenues TTM
$66,569,000,000
NetIncome TTM
$3,173,000,000
OpCashFlow TTM
—
Assets (Latest)
$129,802,000,000
Forward EPS
$8.98
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $140.00 · spot: $137.78 · call volume: 10,630 · put volume: 1,054
Expected Move to 2027-01-15:
±$13.79
(10.01%) —
implied range
$123.99 –
$151.57
· ATM straddle on $140.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NVS | NOVARTIS AG | $302.46B | $159.13 | — |
| AZN | ASTRAZENECA PLC | $282.68B | $182.27 | — |
| ABBV | AbbVie Inc. | $517.59B | $292.82 | — |
| JNJ | JOHNSON & JOHNSON | $670.92B | $278.70 | — |
| ABT | ABBOTT LABORATORIES | $181.35B | $104.71 | — |
News headlines (Yahoo Finance, 1h cache)
What Does Merck (MRK) Losing Nemtabrutinib Mean For Its Blood Cancer Pipeline?
2026-11-19 00:14 · Yahoo
Top Stock Reports for Merck, Caterpillar & Union Pacific
2026-11-18 20:27 · Yahoo
Merck Ends Nemtabrutinib Development: What's Next for Its Pipeline?
2026-11-18 14:36 · Yahoo
Allergy Clinical Trial Services Global Market Report 2026: $1.66 Billion Forecast to 2030 | Capitalize on AI and Remote Trials with J&J, Merck, Sanofi, Novartis, and GSK
2026-11-18 14:35 · Yahoo
Thomas H. Glocer to Retire From Merck Board of Directors in May 2027; Douglas M. Baker, Jr. Appointed Independent Lead Director
2026-11-18 11:45 · Yahoo
Merck Announces Update on BELLWAVE Clinical Development Program Evaluating Nemtabrutinib
2026-11-17 21:15 · Yahoo
How Investors May Respond To Merck (MRK) Pipeline Progress
2026-11-17 17:13 · Yahoo
Merck Announces First-Quarter 2027 Dividend
2026-11-17 15:01 · Yahoo
Merck Stock's $1.3 Billion China Problem Goes Quiet
2026-11-17 14:40 · Yahoo
Moderna Targets Year-End Cancer Therapy Filing, Sees Multibillion-Dollar Opportunity
2026-11-18 13:13 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.